ReviewMolecular psychiatry2008
Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles.
Review in Molecular psychiatry, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 207 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
207 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Systematic Review: Antipsychotic Medication in Pregnancy and Neurodevelopmental Outcomes in Children.Journal of the American Academy of Child and Adolescent Psychiatry · 2026Pooled it
- Effects of Aerobic, Resistance, and Combined Exercise Training on Psychiatric Symptom Severity and Related Health Measures in Adults Living With Schizophrenia: A Systematic Review and Meta-Analysis.Frontiers in cardiovascular medicine · 2021Pooled it
- A systematic review of antipsychotic drug effects on human gene expression related to risk factors for cardiovascular disease.The pharmacogenomics journal · 2014Pooled it
- Pooled it
- Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis.Drug safety · 2012Pooled it
- Pooled it
- Paliperidone for schizophrenia.The Cochrane database of systematic reviews · 2008Pooled it
- Probiotics Plus Dietary Fiber Supplements Attenuate Olanzapine-Induced Weight Gain in Drug-Naïve First-Episode Schizophrenia Patients: Two Randomized Clinical Trials.Schizophrenia bulletin · 2022Trial
- Trial
- A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia.The international journal of neuropsychopharmacology · 2018Trial
- Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study.Psychopharmacology · 2017Trial
- Population pharmacokinetics of JNJ-37822681, a selective fast-dissociating dopamine D₂-receptor antagonist, in healthy subjects and subjects with schizophrenia and dose selection based on simulated D₂-receptor occupancy.Clinical pharmacokinetics · 2013Trial
- Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease.Diabetes · 2013Trial
- Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia.Acta psychiatrica Scandinavica · 2013Trial
- Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder: preliminary findings.Psychopharmacology · 2008Trial
- Adjunctive Pharmacotherapy for Major Depressive Disorder with Anxiety Symptoms: from Monoamines to Recent Clinical Evidence.CNS drugs · 2026Review
- Article
- Review
- Heterogeneity in adverse events associated with lumateperone: a study on potential subgroup-specific differences.The international journal of neuropsychopharmacology · 2026Article
- Trip killers: Addressing a critical knowledge gap in psychedelic research.Journal of psychopharmacology (Oxford, England) · 2026Review
147 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atypical antipsychotic drugs offer several notable benefits over typical antipsychotics, including greater improvement in negative symptoms, cognitive function, prevention of deterioration, and quality of life, and fewer extrapyramidal symptoms (EPS). However, concerns about EPS have been replaced by concerns about other side effects, such as weight gain, glucose dysregulation and dyslipidemia. These side effects are associated with potential long-term cardiovascular health risks, decreased medication adherence, and may eventually lead to clinical deterioration. Despite a greater understanding of the biochemical effects of these drugs in recent years, the pharmacological mechanisms underlying their various therapeutic properties and related side effects remain unclear. Besides dopamine D(2) receptor antagonism, a characteristic feature of all atypical antipsychotic drugs, these agents also bind to a range of non-dopaminergic targets, including serotonin, glutamate, histamine, alpha-adrenergic and muscarinic receptors. This review examines the potential contribution of different receptors to metabolic side effects associated with atypical antipsychotic treatment for all seven agents currently marketed in the United States (risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, paliperidone and clozapine) and another agent (bifeprunox) in clinical development at the time of this publication.
Indexed as
Identifiers
17848919What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.